Pandemic (H1N1) 2009 influenza virus induces weaker host immune responses in vitro: a possible mechanism of high transmissibility
© Mukherjee et al; licensee BioMed Central Ltd. 2011
Received: 19 November 2010
Accepted: 25 March 2011
Published: 25 March 2011
The world has recently overcome the first influenza pandemic of the 21st century caused by a novel H1N1 virus (pH1N1) which is a triple reassortant comprising genes derived from avian, human, and swine influenza viruses and antigenically quite different from seasonal H1N1 strains. Although the case fatality rates have decreased in many developed countries, the situation is still alarming in many developing countries including India where considerable numbers of new cases are appearing everyday. There is still a high morbidity and mortality of susceptible adult as well as young population without having underlying health issues due to the influenza infection.
To achieve a better understanding of the risk posed by the pH1N1 and to understand its pathogenicity, we studied the host gene expression response to Indian isolate of pH1N1 infection and compared it with seasonal H1N1 infection. The response was studied at four different time points (4, 8, 16 and 24 h) post infection (hpi) in A549 cells using microarray platform. We found that pH1N1 induces immune response earlier than seasonal H1N1 viruses, but at the later stages of infection there is a suppression of host immune responses. The infection with pH1N1 resulted in considerable decrease in the expression of cytokine and other immune genes namely IL8, STAT1, B2 M and IL4 compared to seasonal H1N1.
We propose that the inability to induce strong innate immune response could be a reason for the high transmissibility, pathogenicity and mortality caused by pH1N1 virus.
The pandemic (H1N1) 2009 influenza A virus (pH1N1) has already killed more than 19,000 people worldwide since it appeared in April 2009 . Although on 10th of August 2010, the Director General of the World Health Organization (WHO) has announced that the world is no longer in phase 6 of influenza pandemic alert and we are now moving into the post-pandemic period, the virus transmission is still highly active in many parts of South Asia, West Africa, and Central America . In Asia, the most active areas of pandemic influenza virus transmission currently are in parts of India, Bangladesh, Bhutan, Myanmar Nepal, and Thailand. The virus (pH1N1) is still a serious threat to children as well as susceptible young and old population in developing countries like India.
Till date, there are reports of 2720 deaths from pandemic H1N1 influenza virus infection in India which is approximately 14% of the total world mortality http://www.virologyj.com/content/8/1/140http://netindian.in/news/2010/11/15/0008699/6-h1n1-deaths-india-during-past-week-govt. The pandemic H1N1 virus is antigenically distinct from seasonal influenza viruses and the majority of human population lacks immunity against this virus [3–5]. The pathogenesis and transmission of the pH1N1 in humans is not completely known and many studies are underway. Animal studies have shown that this virus has a higher replicative power than the seasonal influenza virus [6, 7]. Studies on human macrophages have shown that pH1N1 is a weak inducer of cytokine responses as compared to seasonal H1N1 viruses . In addition, pH1N1 replicates efficiently in non-human primates, causes more severe pathological lesions in the lungs than currently circulating seasonal human H1N1 virus [9, 10]. Earlier findings indicate that pandemic H1N1 are more pathogenic in mammalian models than seasonal H1N1 influenza viruses [6–8, 11–13]. The pH1N1 isolates tested in mice and ferrets, were found to be replicating more efficiently than currently circulating human H1N1 viruses [6–8].
The respiratory tract is the primary site of infection for all the mammalian influenza viruses [13, 14]. In this study we have used human lung epithelial cells (A549) to study the host gene expression responses to infection with Indian isolate of pH1N1, isolated in August 2009 and compared it with seasonal H1N1 infection in order to assess the pathogenicity and transmissibility of pandemic (2009) H1N1 influenza virus.
Materials and methods
Viruses and cell line
Pandemic Influenza virus A/Jalna/NIV9436/2009 (H1N1) and seasonal human influenza virus A/NIV/0914864/2009(H1N1) isolated in the influenza division of the National Institute of Virology, Pune, India were used for the study. Human lung epithelial (A549) cell line was used as host and maintained in Dulbecco's modified Eagle's tissue culture medium (Invitrogen Life Technologies, Carlsbad, CA, USA) containing 10% fetal calf serum,100 units/ml penicillin, 100 ug/ml streptomycin in tissue culture flasks (Corning, USA) at 37°C in a CO2 incubator.
A549 cells were infected with pH1N1 and seasonal influenza viruses at a multiplicity of infection (MOI) of 3 as described earlier . After 1 hour of adsorption period, the inoculum was removed and the cells were washed twice with phosphate buffer saline (PBS) and supplemented with growth media. Four sets of tissue culture flasks containing monolayer of A549 cells were infected corresponding to four different time points post infection for both the viruses. Mock infected cells at each time point served as controls. Infection of pH1N1 was performed in BSL-2 laboratory following World Health Organization norm for handling of pandemic H1N1 viruses.
Infected cells were harvested at different time points post infection, total RNA was extracted from the infected cells at 4, 8, 16 and 24 hpi using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and purified using the RNeasy kit (Qiagen, Germany). Amplification of RNA and indirect labeling of Cy-dye was done using Amino Allyl MessageAmp II aRNA amplification kit (Ambion, Austin, TX, USA) following manufacturer's instruction. One hundred nanograms of total RNA from control and infected cells were used for the experiments. The RNA was reverse transcribed and amplified according to manufacturer's protocol. The purified amino allyl aRNA was labeled with Cy3 and Cy5 for control and experimental samples respectively. Purified samples were lyophilized, resuspended in hybridization buffer (Pronto Universal Hybridization kit, Corning) and hybridized on human Discover chip (Arrayit corporation, Sunnyvale, CA, USA). Hybridization was carried out in a Hybstation (Genomic Solutions, Ann Arbor, MI) and the conditions used were 55°C for 6 h, 50°C for 6 h, and 42°C for 6 h. Scanning was performed at 5-micron resolutions with the Scan array express (PerkinElmer, Waltham, MI). Grid alignment was done by gene annotation files and raw data were extracted into MS EXCEL .
Microarray data analysis was carried out with GENOWIZ Microarray data and pathway analysis tool (Ocimum Biosolutions, Hyderabad, India). Replicated values for genes were merged and median values of the expression ratios were considered for the dataset. Undetected spots were removed by filtering. Dye bias was nullified by applying Loess normalization. Log transformation (log2) was done to stabilize the variation in dataset and median centering was performed to bring down data distribution of dataset close to zero. In order to detect highly expressed genes, fold change analysis was done. Genes with 1.5 folds up/down-regulation were considered as differentially expressed at a p-value <0.05, Student's t-test. Functional classification of the genes was performed using gene ontology and pathway analysis .
Quantitative RT-PCR of host genes using SYBR Green I
Microarray gene expression data was validated by quantitative RT-PCR as described earlier . The PCR reaction was performed in triplicates using ABI 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA) with Quanti Tect SYBR green RT-PCR kit (Qiagen, Germany). Reaction efficiency was calculated by using serial 10-fold dilutions of the housekeeping gene- β-actin and the sample genes. Melting curve analysis was performed to verify product specificity. All quantitations (threshold cycle [CT] values) were normalized to that of β-actin to generate ΔCT, and the difference among the ΔCT value of the sample and that of the reference (uninfected sample) was calculated as -ΔΔCT. The relative level of gene expression was expressed as 2-ΔΔCT. Primer sequences for the genes of interest were obtained from primer bank and also designed using Primer Express (Applied Biosystems). The primer sequences used in this study are as follows:
Beta-Actin_F 5'- CATGAAGTGTGACGTGGACATCC-3'; Beta-Actin_R 5'-GCTGATCCACATCTGCTGGAAGG-3'; TNFRSF1A_F 5'-TTGCATCCTAGCCCAGCAG-3'; TNFRSF1A_R 5'-CTGACCCTGGAAAGAAAAGTC-3'; IL8_F 5'-TGCCAAGGAGTGCTAAAG-3'; IL8_R 5'-CTCCACAACCCTCTGCAC-3';B2 M (Beta-2-microglobin)_F 5'-ATGTCTCGCTCCGTGGCCTTA-3'; B2 M (Beta-2-microglobin)_R 5'-ATCTTGGGCTGTGACAAAGTC-3'; STAT1_F 5'- CCATCCTTTGGTACAACATGC-3'; STAT1_R 5'-TGCACATGGTGGAGTCAGG-3'; IFNβ_F 5'-CAGCAATTTTCAGTGTCAGAAGC-3'; IFNβ_R 5'-TCATCCTGTCCTTGAGGCAGT-3'.
Western Blot analysis
Total cellular protein from control and infected A549 cells at different time points post infection were isolated using RIPA lysis buffer. Equal amount of proteins (10 μg) from cell extracts were separated by 12.5% SDS-polyacrylamide gel electrophoresis (12.5% SDS-PAGE) and transferred to Hybond-C (Amersham Biosciences) membrane with an electrotransfer apparatus (Cleaver Scientific Ltd) at 10 Volts (100 mA) for 1 h 30 min. Primary and secondary antibody interaction was performed in phosphate-buffered saline (pH 7.5). Primary antibodies used were rabbit anti-STAT1, mouse anti-CASP3 and mouse anti-β-actin antibody (Santa Cruz Biotechnology, Inc. Santa Cruz, CA. USA). The secondary antibodies were mouse anti-rabbit and goat anti-mouse secondary antibodies (Santa Cruz Biotechnology, Inc. Santa Cruz, CA. USA) labeled with Horseradish peroxidase (HRP). The protein bands were developed with 3, 3'-Diaminobenzidine tetrahydrochloride (DABT) and Hydrogen peroxide (H2O2) staining.
Host gene expression profile in response to pandemic (H1N1) 2009 virus infection
Significantly enriched Gene Ontology terms in response to infection with pandemic H1N1(2009) and seasonal H1N1 influenza viruses
A. Pandemic H1N1
A. Seasonal H1N1
regulation of cell proliferation
regulation of apoptosis
regulation of apoptosis
regulation of cell proliferation
positive regulation of apoptosis
response to cytokine stimulus
regulation of cell cycle
regulation of protein kinase activity
negative regulation of apoptosis
lymphocyte activation and immune response
protein amino acid phosphorylation
cytokine-mediated signaling pathway
positive regulation of signal transduction
immune system development
positive regulation of transcription from RNA polymerase II promoter
transmembrane receptor protein tyrosine kinase signaling pathway
regulation of DNA replication
regulation of I-kappaB kinase/NF-kappaB cascade
positive regulation of B cell activation
At the early stages of virus infection i.e. at 4 hpi, we found up-regulation of immune genes like TNF-α 3, EGR-1, IL6R, v-FOS, v-JUN. However, IL13RA, IL3RA, IL4, STAT1, STAT4 were down-regulated at this time point of infection. At 8 hpi there was further increase in the expression of EGR-1, IL6R, TNF-α 3, v-FOS and v-JUN genes and up-regulation of other immune responsive genes like IL-8. Surprisingly, we observed more number of immune genes getting down-regulated at this stage as compared to 4 hpi. The down-regulation of this set of immune genes was more prominent at later stages (16 and 24 hpi) of infection with pandemic H1N1. Genes involved in intracellular signaling and DNA repair like Topoisomerase II, MAP2K6 were also found to be down-regulated at 8 hpi. Higher expression of IL8, TNF-α 3, TNFR-6, CXCR4, EGR-1, v-JUN was found at 16 hpi. Gene coding for IL13RA showed continued down-regulation at this stage of infection. Interestingly, at 24 h post infection there was no further increase in immune responsive genes but down-regulation of STAT4, TNFR, IL4R, and TNF6 genes were found.
Host gene expression profile in response to seasonal H1N1 virus infection
Summary of genes differentially expressed in response to infection with pandemic and seasonal H1N1 viruses
Time-points post infection
Genes qualifying quality criteria in replicated experiments
Differentially expressed genes (+/- 1.5 folds, p < 0.05)
At 4 hour post infection with seasonal H1N1, genes encoding for the ribosomal proteins and DNA modifying enzymes were up-regulated and continued to be up-regulated at all the time points post infection studied in this experiment. Increased level of the expression of immune genes was observed from 16 hpi. Cytokines like CCL5, small inducible cytokine A2, IL8 and other immune responsive genes like STAT1, IRF1 and B2 M were found to be up-regulated at this time point post infection with seasonal influenza virus. At 24 hpi there was further increase in the expression of immune and ribosomal genes. There was up-regulation of additional transcription factors and signaling molecules at 24 hpi. However, some of the cytokines, signaling genes and DNA repair genes were selectively down regulated at all the post infection time points. These genes mainly included IGF2R, Topoisomerase I and IL13RA1. Genes involved in cell cycle like Cyclin G1, G2 were down-regulated at all the time points post infection.
Comparative analysis of host gene expression responses between pH1N1 and seasonal H1N1 infection
Validation of Microarray data using Real Time PCR and Western blot analysis
Global spread of pandemic (2009) influenza A (H1N1) virus was found to be much faster as compared to earlier pandemics. Rapid transmission of the pandemic H1N1 virus, its efficiency to infect hundreds of millions of people worldwide and its impact in public health during the peak pandemic period prompted us to initiate study on host gene expression profile to pandemic H1N1 infection in human lung epithelial cells using microarray platform.
In the present study we have compared the host gene expression responses to pandemic H1N1 and seasonal H1N1 virus infection in lung epithelial (A549) cells. Functional analysis of differentially expressed genes in both the infections revealed qualitative similarity in the gene expression profiles i.e. the type of genes affected were found similar between the two virus infections (Table 1A and 1B). However, there was quantitative difference in the number of differentially expressed genes in pH1N1 and seasonal H1N1 infections. The number of differentially expressed genes in response to seasonal H1N1 infection was higher than that of the pH1N1 at all the time points. This indicates that higher numbers of host genes were getting influenced by seasonal H1N1 than the pandemic H1N1 virus infection. There was a difference in the infection stage at which the genes involved in host immune response were activated during the pandemic and seasonal influenza virus infections. We observed up-regulation of immune genes at early stages of pH1N1 virus infection compared to seasonal H1N1.
However, later stages of infection with pH1N1 were accompanied by a characteristic impairment of the innate immune responses (Figure 2 and Figure 3) characterized by defective cytokine responses as compared to seasonal H1N1. The high infectivity of pandemic H1N1 in animal models as observed in other studies [7, 8] could be due to a better subversion of host immune responses by this virus. Cytokine and interferon genes which are important components of innate immunity  were also found to be down-regulated at later stages of infection with pH1N1. Similar decrease in immune response during pandemic (H1N1) 2009 virus infection has been reported earlier also . Expression of IFN-β gene, which is an important host defense gene, was analyzed by Real-time PCR (Figure 5). IFN-β is the most potent antiviral cytokine and is massively produced during Influenza A virus infection . Virus should have capability to overcome antiviral action of interferon during its course of infection in order to replicate efficiently. We found that both the viruses have the property of antagonizing INF-β, but pH1N1 infection results in stronger suppression of host INF-β expression at early stages (4 hpi) as compared to seasonal H1N1. Also, suppression of INF-β was stronger at later stages (24 hpi) of pandemic virus infection. These observations indicate greater replicative ability of pandemic viruses in the host cells as compared to seasonal H1N1 (Figure 5). An early activation of Caspase 3 (Figure 6) is indicative of an early host response to seasonal H1N1 infection as compared to pH1N1. However, at the later stages higher level Caspase 3 expression by pH1N1 infection could be a viral mediated response and the overall Caspase 3 expression pattern indicates a differential ability of the two viruses to induce apoptosis. Probably pH1N1 inhibit apoptosis in the early stages of infection and utilizes cellular machinery more efficiently to get a better replicative ability as compared to seasonal H1N1 virus infection.
To further validate the differences in the host immune responses to seasonal H1N1 and pH1N1 virus infection, we studied the expression of STAT1 protein (Figure 6). STAT1 protein is an important component of Jak-Stat pathway which gets activated at later stages of virus infection. Activation of Jak-Stat pathway results in stimulation of Interferon regulatory genes leading to heightened immune responses [16, 18]. We observed higher expression of STAT1 protein in seasonal H1N1 infection at later stages as compared to pH1N1 (Figure 6). This is indicative of suppression of STAT1 at later stages of pandemic H1N1 virus infection, which might decrease the overall host innate immune response. On the other way, suppression of STAT1 leads to inhibition of interferon regulatory genes allowing rapid replication and consequent spread of pH1N1 compared to seasonal H1N1. NS1 protein of influenza virus is a very important component to antagonize host interferon activity to lead virus replication. The pathogenicity and transmission of influenza A viruses are likely determined in part by replication efficiency in human cells, which is the net effect of complex virus-host interactions. A recent study have shown that the influenza A virus that circulate in human differ markedly in the ability of their NS1 protein to block the activation of interferon regulatory gene (IRF3) and interferon beta transcription . Probably NS1 protein of pH1N1 is more potent in antagonizing host interferon activity compared to seasonal H1N1 viruses in mammalian cell line (A549) which facilitates rapid viral replication.
Indian isolates of 2009 pandemic H1N1, although overall similar to Mexican strain is reported to cause greater mortality in India on the basis of clinical records. During the peak pandemic period almost 90% cases were found positive for pH1N1 in New York City and other many other regions. However, both seasonal-H1N1 and pandemic H1N1 were represented in almost equal proportion in Indian population during the peak pandemic period . Although many gaps remain in understanding how a pandemic influenza virus behaves, spread and affect the community, in Indian scenario, along with viral factors other socio-economic and environmental factors may also be involved in high pathogenesis of pandemic H1N1 virus.
It is well established that pH1N1 is highly transmissible as it has rapidly spread to large number of countries within a very short period of time. We propose that high transmissibility of pandemic H1N1 virus in the year 2009-2010 is because of its better subversion of host immune responses compared to the seasonal influenza viruses. Additionally, lack of earlier immunity to pH1N1 virus makes it more pathogenic as compared to seasonal H1N1.
(hours post infection)
(amino allyl amplified RNA)
The authors are grateful to Dr.M.S Chadha, Influenza Group, National Institute of Virology, Pune, India for her support in this study. The authors are also thankful to Mr. Subhashis Chatterjee for his help. The study was supported by the Indian Council of Medical Research, Government of India.
- World Health Organization: Cumulative number of confirmed human death cases of pandemic influenza A/(H1N1) reported to WHO.World Health Organization Geneva, Switzerland; 2010. [http://www.who.int/csr/disease/influenza/update/en/]Google Scholar
- World Health Organization in South-East Asia region: Total positive test reports of Pandemic (H1N1) 2009 received in SEAR up to August 01, 2010.[http://www.searo.who.int/EN/Section10/Section2562.htm]
- Girard MP, Tam JS, Assossou OM, Kieny MP: The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010, 28: 4895-902. 10.1016/j.vaccine.2010.05.031View ArticlePubMedGoogle Scholar
- Lu L, Yin Y, Sun Z, Gao L, Gao GF, Liu S, Sun L, Liu W: Genetic correlation between current circulating H1N1 swine and human influenza viruses. J Clin Virol 2010, 49: 186-91. 10.1016/j.jcv.2010.07.018View ArticlePubMedGoogle Scholar
- Potdar VA, Chadha MS, Jadhav SM, Mullick J, Cherian SS, Mishra AC: Genetic characterization of the influenza A pandemic (H1N1) 2009 virus isolates from India. PLoS One 2010, 5: e9693. 10.1371/journal.pone.0009693PubMed CentralView ArticlePubMedGoogle Scholar
- Rowe T, León AJ, Crevar CJ, Carter DM, Xu L, Ran L, Fang Y, Cameron CM, Cameron MJ, Banner D, Ng DC, Ran R, Weirback HK, Wiley CA, Kelvin DJ, Ross TM: Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology 2010, 401: 257-65. 10.1016/j.virol.2010.02.020PubMed CentralView ArticlePubMedGoogle Scholar
- Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, et al.: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460: 1021-1038.PubMed CentralPubMedGoogle Scholar
- Osterlund P, Pirhonen J, Ikonen N, Rönkkö E, Strengell M, Mäkelä SM, Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I: Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 2010, 84: 1414-22. 10.1128/JVI.01619-09PubMed CentralView ArticlePubMedGoogle Scholar
- Baskin CR, Bielefeldt-Ohmann H, Tumpeye TM, Sabourin PJ, Long JP, García-Sastre A, Tolnayd A, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG: Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009, 106: 3455-3460. 10.1073/pnas.0813234106PubMed CentralView ArticlePubMedGoogle Scholar
- Cillóniz C, Shinya K, Peng X, Korth MJ, Proll SC, Aicher LD, Carter VS, Chang JH, Kobasa D, Feldmann F, Strong JE, Feldmann H, Kawaoka Y, Katze MG: Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 2009, 10: e1000604.View ArticleGoogle Scholar
- Bermejo-Martin JF, Martin-Loeches I, Rello J, Antón A, Almansa R, Xu L, Lopez-Campos G, Pumarola T, Ran L, Ramirez P, Banner D, Cheuk Ng D, Socias L, Loza A, Andaluz D, Maravi E, Gómez-Sánchez MJ, Gordón M, Gallegos MC, Fernandez V, Aldunate S, León C, Merino P, Blanco J, Martin-Sanchez F, Rico L, Varillas D, Iglesias V, Marcos MA, Gandía F, Bobillo F, Nogueira B, Rojo S, Resino S, Castro C, Ortiz de Lejarazu R, Kelvin D: Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 2010, 14: R167. 10.1186/cc9259PubMed CentralView ArticlePubMedGoogle Scholar
- Giamarellos-Bourboulis EJ, Raftogiannis M, Antonopoulou A, Baziaka F, Koutoukas P, Savva A, Kanni T, Georgitsi M, Pistiki A, Tsaganos T, Pelekanos N, Athanassia S, Galani L, Giannitsioti E, Kavatha D, Kontopidou F, Mouktaroudi M, Poulakou G, Sakka V, Panagopoulos P, Papadopoulos A, Kanellakopoulou K, Giamarellou H: Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One 2009, 4: e8393. 10.1371/journal.pone.0008393PubMed CentralView ArticlePubMedGoogle Scholar
- Lee SMY, Gardy JL, Cheung CY, Cheung TKW, Hui KPY, Ip NY, Guan Y, Hancock REW, Peiris JSM: Systems-Level Comparison of Host-Responses Elicited by Avian H5N1 and Seasonal H1N1 Influenza Viruses in Primary Human Macrophages. PLoS One 2009, 4: e8072. 10.1371/journal.pone.0008072PubMed CentralView ArticlePubMedGoogle Scholar
- Mansfield KG: Viral Tropism and the Pathogenesis of Influenza in the Mammalian Host. American Journal of Pathology 2007, 171: 1089-1092. 10.2353/ajpath.2007.070695PubMed CentralView ArticlePubMedGoogle Scholar
- Chakrabarti AK, Vipat VC, Mukherjee S, Singh R, Pawar SD, Mishra AC: Host gene expression profiling in influenza A virus-infected lung epithelial (A549) cells: A comparative analysis between highly pathogenic and modified viruses. Virol J 2010, 7: 219. 10.1186/1743-422X-7-219PubMed CentralView ArticlePubMedGoogle Scholar
- Koyama S, Ishii KJ, Coban C, Akira S: Innate immune response to viral infection. Cytokine 2008, 43: 336-341. 10.1016/j.cyto.2008.07.009View ArticlePubMedGoogle Scholar
- Arankalle VA, Lole KS, Arya RP, Tripathy AS, Ramdasi AY, Chadha MS, Sangle SA, Kadam DB: Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One 2010, 5: e13099. 10.1371/journal.pone.0013099PubMed CentralView ArticlePubMedGoogle Scholar
- Le Goffic RL, Bouguyon E, Chevalier C, Vidic J, Da Costa B, Leymarie O, Bourdieu C, Decamps L, Dhorne-Pollet S, Delmas B: Influenza A Virus Protein PB1-F2 exacerbates IFN-b Expression of Human Respiratory Epithelial Cells. J Immunol 2010, 185: 4812-4823. 10.4049/jimmunol.0903952View ArticlePubMedGoogle Scholar
- Kuo RL, Zhao C, Malur M, Krug RM: Influenza A virus strains that circulate in humans differ in the ability of their NS1 proteins to block the activation of IRF3 and interferon-β transcription. J Virol 2010, 408: 146-158. 10.1016/j.virol.2010.09.012View ArticleGoogle Scholar
- Mishra AC, Chadha MS, Choudhary ML, Potdar VA: Pandemic Influenza (H1N1) 2009 Is Associated with Severe Disease in India. PLoS One 2010, 5: e10540. 10.1371/journal.pone.0010540PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.